Customized Choice of Oral P2Y12 Receptor Blocker

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.

Also called NCT01477775

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 4,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01477775
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01477775. Randomized; no masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Customized Choice of Oral P2Y12 Receptor Blocker
Acronym
PRU-MATRIX
Condition
Acute Coronary Syndrome
Condition
Coronary Angioplasty
Intervention (Drug)
Oral P2Y12 receptor blocker
Intervention (Drug)
Customized choice for the oral P2Y12 receptor blocker
Lead sponsor
Italian Society of Invasive Cardiology (class: other)
Collaborator
Eustrategy (class: other)

Record details

Record id
cardio:ct-nct01477775
Content hash
3b6aff832529d029fb758f8c21842871766c2b6deb0e89ce1c298bac3bf4085f